Genetronics' CE-marks electroporation device:
This article was originally published in Clinica
Genetronics Biomedical has CE-marked its MedPulser electroporation device used in the treatment of solid tumours. The product provides electrical pulses to the tumour, causing the cell pores to open temporarily. This allows the delivery of the chemotherapy drug bleomycin to the cancer site. The CE-marking triggers a milestone payment from Ethicon, Genetronics' marketing partner.
You may also be interested in...
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.